blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3964238

EP3964238 - BCMA-TARGETING ENGINEERED IMMUNE CELL AND USE THEREOF [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  18.08.2023
Database last updated on 29.06.2024
FormerRequest for examination was made
Status updated on  04.02.2022
FormerThe international publication has been made
Status updated on  14.11.2020
Most recent event   Tooltip28.05.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Gracell Biotechnologies (Shanghai) Co., Ltd.
12th Floor Building 1 926 Yishan Road
Xuhui District
Shanghai 200233 / CN
[2022/10]
Inventor(s)01 / ZHANG, Hua
12th Floor, Building 1, 926 Yishan Road, Xuhui
District
Shanghai 200233 / CN
02 / SHEN, Lianjun
12th Floor, Building 1, 926 Yishan Road, Xuhui
District
Shanghai 200233 / CN
03 / SHI, Huan
12th Floor, Building 1, 926 Yishan Road, Xuhui
District
Shanghai 200233 / CN
04 / CAO, Wei
12th Floor, Building 1, 926 Yishan Road, Xuhui
District
Shanghai 200233 / CN
05 / YANG, Chunhui
12th Floor, Building 1, 926 Yishan Road, Xuhui
District
Shanghai 200233 / CN
06 / LIU, Liping
12th Floor, Building 1, 926 Yishan Road, Xuhui
District
Shanghai 200233 / CN
 [2022/10]
Representative(s)Santoro, Sofia, et al
Società Italiana Brevetti S.p.A.
Via Giosuè Carducci, 8
20123 Milano / IT
[N/P]
Former [2022/10]Rondano, Davide, et al
Società Italiana Brevetti S.p.A.
Via Carducci 8
20123 Milano / IT
Application number, filing date20803022.106.05.2020
[2022/10]
WO2020CN88835
Priority number, dateCN20191037664507.05.2019         Original published format: CN201910376645
[2022/10]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020224605
Date:12.11.2020
Language:ZH
[2020/46]
Type: A1 Application with search report 
No.:EP3964238
Date:09.03.2022
Language:EN
[2022/10]
Search report(s)International search report - published on:CN12.11.2020
(Supplementary) European search report - dispatched on:EP11.08.2022
ClassificationIPC:A61K48/00, A61K39/00, C12N5/0783, C12N15/86, C07K16/28, C07K16/30, C12N15/09, A61P35/00
[2022/37]
CPC:
A61P35/00 (EP,US); A61K35/17 (US); A61K39/4611 (EP);
A61K39/4631 (EP); A61K39/464412 (EP); A61K39/464417 (EP);
A61K48/005 (EP); C07K16/2803 (EP,US); C07K16/2878 (EP,US);
C12N15/86 (EP,US); C12N5/0636 (EP); A61K2039/572 (EP);
A61K2239/28 (EP); A61K2239/29 (EP); A61K2239/38 (EP);
A61K2239/46 (EP); C07K2317/622 (EP); C07K2319/03 (EP);
C07K2319/33 (EP); C12N2510/00 (EP); C12N2740/16043 (EP) (-)
Former IPC [2022/10]A61K48/00, C07K16/28, C07K16/30, C12N15/09, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/10]
TitleGerman:AUF BCMA ABZIELENDE MANIPULIERTE IMMUNZELLE UND VERWENDUNG DAVON[2022/10]
English:BCMA-TARGETING ENGINEERED IMMUNE CELL AND USE THEREOF[2022/10]
French:CELLULE IMMUNITAIRE MODIFIÉE CIBLANT BCMA ET SON UTILISATION[2022/10]
Entry into regional phase02.12.2021Translation filed 
02.12.2021National basic fee paid 
02.12.2021Search fee paid 
02.12.2021Designation fee(s) paid 
02.12.2021Examination fee paid 
Examination procedure02.12.2021Examination requested  [2022/10]
08.03.2023Amendment by applicant (claims and/or description)
22.08.2023Despatch of a communication from the examining division (Time limit: M06)
01.03.2024Reply to a communication from the examining division
Fees paidRenewal fee
02.12.2021Renewal fee patent year 03
26.05.2023Renewal fee patent year 04
27.05.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XY]WO2017211900  (MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN [DE], et al) [X] 1,2,7-9,11,12 * figure 13; claims 1-5 * [Y] 3-6,10;
 [XY]CN108004259  (SHANGHAI HENGRUN DASHENG BIOTECHNOLOGY CO LTD) [X] 1,2,7-9,11,12 * figure 1; claims 1-10; sequence 2 * [Y] 3-6,10;
 [XY]CN108285489  (SHANGHAI HENGRUN DASHENG BIOLOGICAL TECH CO LTD) [X] 1,2,7-9,11,12 * figure 1; claims 1-10; sequence 2 * [Y] 3-6,10;
 [Y]CN109468283  (BEIJING MEIKANG JIMIAN BIOTECHNOLOGY CO LTD) [Y] 3-6,10 * figure 1; claims 1-10; sequence 1 *;
 [Y]CN109485734  (GUANGZHOU BIO GENE TECH CO LTD) [Y] 3-6,10 * figure 1; claims 1-10 *;
 [XPY]WO2019241358  (UNIV CALIFORNIA [US]) [XP] 1-3,5,7-12 * paragraph [0319]; figures 1B, 13; claims 10-29; sequences 33, 34 * [Y] 4,6;
 [XY]  - JULIA BLUHM ET AL, "CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma", MOLECULAR THERAPY, US, (201808), vol. 26, no. 8, doi:10.1016/j.ymthe.2018.06.012, ISSN 1525-0016, pages 1906 - 1920, XP055625080 [X] 1,2,7-9,11,12 * page 1907; figure 1 * [Y] 3-6,10

DOI:   http://dx.doi.org/10.1016/j.ymthe.2018.06.012
 [A]  - CHO SHIH-FENG ET AL, "BCMA CAR T-cell therapy arrives for multiple myeloma: a reality", ANNALS OF TRANSLATIONAL MEDICINE, US, vol. 6, no. S2, doi:10.21037/atm.2018.11.14, ISSN 2305-5839, (201812), pages S93 - S93, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330615/pdf/atm-06-S2-S93.pdf, XP055948602 [A] 1,2,7-9,11,12 * the whole document *

DOI:   http://dx.doi.org/10.21037/atm.2018.11.14
International search[Y]CN105142677  (UNIV CALIFORNIA) [Y] 3-12* entire document, especially claims, SEQ ID NO: 6 and the abstract *;
 [X]CN108395478  (SHANGHAI HRAIN BIOTECHNOLOGY CO LTD) [X] 1, 2, 7-9, 11, 12 * entire document, especially claims, SEQ ID NO: 1 and the abstract *;
 [Y]CN108395478  (SHANGHAI HRAIN BIOTECHNOLOGY CO LTD) [Y] 3-12 * entire document, especially claims, SEQ ID NO: 1 and the abstract *;
 [Y]  - ZHANG, Feng et al., "Development in Bispecific Antibody", Chinese Journal of Pharmaceutical Analysis, (20190131), vol. 39, no. 1, pages 78 - 85, XP009522265 [Y] 5, 6 * figure 1, and abstract *

DOI:   http://dx.doi.org/10.16155/j.0254-1793.2019.01.10
by applicantUS5350674
 US5399346
 US5580859
 US5585362
 US5589466
 WO0129058
 US6326193
 WO2010104949
 CN105658671
    - UI-TEI et al., FEBS Letters, (20000000), vol. 479, pages 79 - 82
    - ROSENBERG et al., NewEng.J. of Med., (19880000), vol. 319, page 1676
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.